<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741698</url>
  </required_header>
  <id_info>
    <org_study_id>DDD# 604829</org_study_id>
    <nct_id>NCT04741698</nct_id>
  </id_info>
  <brief_title>Propranolol for Protracted Labor</brief_title>
  <acronym>PRO-Labor</acronym>
  <official_title>Propranolol for Prolonged Labor: A Randomized Controlled Trial (PRO-Labor Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christiana Care Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Christiana Care Health Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Induction of labor is one of the most common procedures performed on labor and delivery. In&#xD;
      the United States, more than 20 percent of pregnant women undergo an induction of labor [1].&#xD;
&#xD;
      There is data from small, randomized studies that demonstrates the effectiveness of&#xD;
      propranolol, a non-selective beta-blocker, for labor augmentation. This literature suggests a&#xD;
      decrease in the amount of time to delivery and a possible reduction in cesarean section rates&#xD;
      when propranolol is used in conjunction with oxytocin for induction of labor compared to&#xD;
      oxytocin alone [2-8].&#xD;
&#xD;
      Alpha- and beta-adrenergic receptors have been identified in the human myometrium.&#xD;
      Propranolol has been shown in studies to enhance uterine contractions and may be a useful&#xD;
      tool in this population of women. Therefore, the purpose of this study is to assess whether&#xD;
      the administration of propranolol at time of labor dystocia reduces time to delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All cervical ripening will be performed in the labor and delivery unit; continuous fetal&#xD;
      heart rate and uterine activity will be monitored in all patients. Cervical dilation is&#xD;
      assigned by admitting physicians. Sonography will be performed to document fetal&#xD;
      presentation.&#xD;
&#xD;
      At the time of prolonged labor, patients meeting inclusion criteria and no exclusion criteria&#xD;
      will be consented. There will be no monetary incentives for participation.&#xD;
&#xD;
      Patients will be randomized to either Propranolol 2mg of IV or expectant management at the&#xD;
      time of induction. Maternal vitals will be collected per standard labor management.&#xD;
&#xD;
      Episodes of uterine activity that are deemed excessive by the physician will be treated with&#xD;
      a standard combination of maneuvers that included a change in maternal position, oxygen&#xD;
      administration, and terbutaline 250 µg subcutaneously. Persistent abnormal fetal heart rate&#xD;
      patterns resulted in intervention by removing the patient from the study. Urgent cesarean&#xD;
      delivery is defined as a cesarean delivery performed during the ripening process for abnormal&#xD;
      fetal heart rate that did not respond to standard maneuvers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to delivery</measure>
    <time_frame>Number of hours from induction to delivery of neonate; up to 72 hours.</time_frame>
    <description>The primary outcome is time to delivery (hours) defined as time from initiation of induction method to delivery time, regardless of mode of delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cesarean delivery rate</measure>
    <time_frame>At time of delivery</time_frame>
    <description>rate of cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal length of stay</measure>
    <time_frame>From time of admission to time of hospital discharge; an average of two days</time_frame>
    <description>from time of admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Bradycardia event</measure>
    <time_frame>at time of delivery</time_frame>
    <description>bradycardia alert during labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chorioamnionitis</measure>
    <time_frame>At time of delivery</time_frame>
    <description>defined by the presence of maternal fever ≥100·4°f in the presence of maternal or fetal tachycardia or fundal tenderness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal admission to ICU</measure>
    <time_frame>At time of delivery</time_frame>
    <description>NICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe respiratory distress syndrome</measure>
    <time_frame>at time of delivery</time_frame>
    <description>defined as intubation and mechanical ventilation for a minimum of 12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal sepsis</measure>
    <time_frame>at time of delivery</time_frame>
    <description>Culture proven-presumed neonatal sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal blood transfusion</measure>
    <time_frame>From time of delivery to time of hospital discharge; up to 6 weeks</time_frame>
    <description>Neonatal blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxic ischemic encephalopathy</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>neonatal HIE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Labour;Obstructed</condition>
  <condition>Labor Dystocia</condition>
  <arm_group>
    <arm_group_label>Propranolol 2mg IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the time of labor dystocia, patients randomized to the treatment arm of propranolol will receive a one-time administration of IV 2mg propranolol in pre-mixed syringes prepared by the pharmacy.&#xD;
The propranolol IV administration recommended in clinical practice guidelines is 1 mg IV over 1 minute. Therefore, total administration time will be 2 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>At the time of labor dystocia, patients randomized to the placebo arm will not receive any intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol 2mg IV</description>
    <arm_group_label>Propranolol 2mg IV</arm_group_label>
    <other_name>Propranolol Hydrochloride</other_name>
    <other_name>Inderal</other_name>
    <other_name>Inderal LA</other_name>
    <other_name>InnoPran XL</other_name>
    <other_name>Hemangeol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  full term (≥37 weeks) gestations determined by routine obstetrical guidelines&#xD;
&#xD;
          -  singleton gestation in cephalic presentation&#xD;
&#xD;
          -  Both nulliparous and multiparous women&#xD;
&#xD;
          -  Intact membranes&#xD;
&#xD;
          -  Bishop score of ≤6 and cervical dilation ≤2cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preterm gestation&#xD;
&#xD;
          -  Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia&#xD;
             in the neonate&#xD;
&#xD;
          -  Any cardiac condition for which β blockade is contraindicated (cardiogenic shock,&#xD;
             sinus bradycardia, and greater than first degree heart block)&#xD;
&#xD;
          -  Known hypersensitivity to propranolol&#xD;
&#xD;
          -  Maternal bradycardia (HR &lt;60bpm)&#xD;
&#xD;
          -  Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol&#xD;
             for hypertension control&#xD;
&#xD;
          -  Systolic blood pressure &lt;90 mmHg, or diastolic blood pressure &lt;50 mmHg&#xD;
&#xD;
          -  Receiving other beta blocker&#xD;
&#xD;
          -  Moderate or severe asthma: as this is a contraindication to beta blocker use&#xD;
&#xD;
          -  Any contraindication to a vaginal delivery&#xD;
&#xD;
          -  fetal demise&#xD;
&#xD;
          -  Multifetal gestation&#xD;
&#xD;
          -  major fetal anomaly&#xD;
&#xD;
          -  prior uterine surgery, previous cesarean section&#xD;
&#xD;
          -  women with HIV, hepatitis C, hepatitis B, and women with medical conditions requiring&#xD;
             an assisted second stage&#xD;
&#xD;
          -  Additional exclusion criteria were as follows: category 3 fetal heart rate tracing,&#xD;
             hemolysis elevated liver enzymes and low platelets (HELLP) syndrome or eclampsia,&#xD;
             growth restriction &lt;10th percentile (based on Hadlock growth curves) with reversal of&#xD;
             flow in umbilical artery Doppler studies, and growth restriction &lt;5th percentile with&#xD;
             elevated, absent, or reversal of flow in umbilical artery Doppler studies.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen B Gomez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christiana Care Health Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen B Gomez, MD</last_name>
    <phone>3027731000</phone>
    <email>helen.gomez@christianacare.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helen B Gomez</last_name>
    <phone>3027731000</phone>
    <email>helengom12@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Christiana Care</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen B Gomez</last_name>
      <phone>305-297-9124</phone>
      <email>helengom12@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moghadam AD, Jaafarpour M, Khani A. Comparison effect of oral propranolol and oxytocin versus oxytocin only on induction of labour in nulliparous women (a double blind randomized trial). J Clin Diagn Res. 2013 Nov;7(11):2567-9. doi: 10.7860/JCDR/2013/5704.3613. Epub 2013 Nov 10. Erratum in: J Clin Diagn Res. 2015 Aug;9(8):ZZ01.</citation>
    <PMID>24392402</PMID>
  </reference>
  <reference>
    <citation>Kashanian M, Fekrat M, Zarrin Z, Ansari NS. A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). J Obstet Gynaecol Res. 2008 Jun;34(3):354-8. doi: 10.1111/j.1447-0756.2008.00790.x.</citation>
    <PMID>18588611</PMID>
  </reference>
  <reference>
    <citation>Pergialiotis V, Frountzas M, Prodromidou A, Prapa S, Perrea DN, Vlachos GD. Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor: a meta-analysis of randomized trials. Arch Gynecol Obstet. 2016 Apr;293(4):721-9. doi: 10.1007/s00404-015-3991-8. Epub 2015 Dec 22. Review.</citation>
    <PMID>26695642</PMID>
  </reference>
  <reference>
    <citation>Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979 Oct 15;135(4):485-9.</citation>
    <PMID>573555</PMID>
  </reference>
  <reference>
    <citation>Sanchez-Ramos L, Quillen MJ, Kaunitz AM. Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor. Obstet Gynecol. 1996 Oct;88(4 Pt 1):517-20.</citation>
    <PMID>8841209</PMID>
  </reference>
  <reference>
    <citation>Meidahl Petersen K, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, Torp-Pedersen C, Poulsen HE. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012 Jul 19;2(4). pii: e001185. doi: 10.1136/bmjopen-2012-001185. Print 2012.</citation>
    <PMID>22815467</PMID>
  </reference>
  <reference>
    <citation>Palomäki O, Uotila J, Tammela O, Kaila T, Lavapuro M, Huhtala H, Tuimala R. A double blind, randomized trial on augmentation of labour with a combination of intravenous propranolol and oxytocin versus oxytocin only. Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):44-9. Epub 2005 Jul 26.</citation>
    <PMID>16051416</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystocia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

